GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKER MARKET FORECAST 2017-2025

  • You are here:
  • Home
  • Reports
  • GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKER MARKET FORECAST 2017-2025

GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKER MARKET FORECAST 2017-2025

The Global Central Nervous System (CNS) market is anticipated to grow from $ 3587 million in 2016 to $8756 million by 2025, at a CAGR of 10.49% between 2016 and 2025. Central nervous system disorders represent a growing socioeconomic burden at a global level, not only in terms of the number of patients but also in terms of the high cost of healthcare systems. The Central Nervous System (CNS) market is primarily driven by following factors:

GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKER MARKET FORECAST 2017-2025

Central Nervous System Biomarker Market by Application (Diagnostic Development, Drug Discovery, and Development, Personalized Medicine Market, Disease Risk Assessment & Other) by Type (Safety Biomarker, Efficacy Biomarker, Validation Biomarker)  by End Users (Hospitals, Eye Clinics, Diagnostic Centers & Patients) Geography

Request free sample

The Global Central Nervous System (CNS) biomarker market is anticipated to grow from $ 3587 million in 2016 to $8756 million by 2025, at a CAGR of 10.49% between 2016 and 2025. Central nervous system disorders represent a growing socioeconomic burden at a global level, not only in terms of the number of patients but also in terms of the high cost of healthcare systems. The Central Nervous System (CNS) biomarker market is primarily driven by following factors:

  • Increasing usage of genomics, metabolomics, proteomics, and bioinformatics
  • Funding for the framework programs for research and development of technology
  • Obesity has to become a major concern
  • Public-private corporation has escalated
  • Upsurge in biomarker market due to FDA supports
  • New innovations and technological advancement in biomarker market
  • Rise in real per capita healthcare

Central Nervous System Biomarker marketThe important driver increasing the growth of the global Central Nervous System (CNS) biomarker Market is the fact that obesity is becoming a major health concern. According to World Health Organization, more than 1.4 billion of adults are overweight around the globe. These numbers are especially rising in the developing regions, and this prevalence is estimated to get worse over the years.

The Applications of Central Nervous System (CNS) biomarker market is used extensively for various purposes. The diagnostic development application market is gaining potential due to increasing application and use of biomarkers for diagnostics. On the other hand, the drug discovery and development application of CNS biomarker are going through a stagnant growth. The drug development and discovery of biomarker and various therapeutic agents is an uncertain, competitive, expensive and time-consuming process. Personalized medicine is one of the emerging fields for CNS biomarker due to its rising application as a diagnostic tool which helps assists in recognizing the precise biological markers. Risk assessment is one of the essential tools that are applied in setting occupational and environmental standards which are working as obstacles in exposure with the aim to safeguard human health. The other application of CNS biomarker includes the research institutes and research centers who indulge in various types of researchers to develop a new and innovative biomarker for enhancing the effectiveness of the CNS biomarker.

Reimbursement Policies distressing the CNS Biomarker Market and CNS Biomarker Test and Diagnostics includes high costs, which are acting as the major factors hindering the Central Nervous System (CNS) biomarker market. Fragmented Medicare reimbursement system also poses a challenge for biomarker market. Coverage decisions in Medicare include the national and local jurisdictions combination which is meant for allowing regional flexibility in reimbursement. However, it is also providing difficulties in establishing uniform policies for reimbursement coverage for some technologies. Biomarker testing is at the center of personalized medicine. Biomarker denotes to any of the molecules of the body which can be measured to evaluate health.

The Global Central Nervous System (CNS) biomarker market segments include types and applications.

Applications are segmented into:

  • Diagnostic Development
  • Drug Discovery and Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

Types are segmented into:

  • Safety biomarker
  • Efficacy biomarker
  • Validation biomarker

End users are segmented into:

  • Hospitals
  • Eye Clinics
  • Diagnostic Centers
  • Patients
  • Other End-users

This report covers the present market conditions and the growth prospects of the global Central Nervous System (CNS) biomarker market for 2017-2025 and considered the revenue generated through the sales of Central Nervous System (CNS) biomarker for applications, types as well as end users by considering 2016 as the base year.

Geographically, the global Central Nervous System (CNS) biomarker market has been segmented on the basis of four major regions, which include:

  • Central Nervous System (CNS) biomarker North America Market – U.S. & Canada
  • Central Nervous System (CNS) biomarker Asia-Pacific Market – China, India, Japan, Rest of APAC
  • Central Nervous System (CNS) biomarker Europe Market – UK, France, Germany, Spain, Italy, Rest of Europe
  • Rest of World- Latin America, Middle East and North Africa, Rest of Africa

The Central Nervous System (CNS) biomarker market in North America is expected to hold the largest share by 2025 on account of the increasing prevalence of lifestyle diseases like Alzheimer’s, cardiovascular diseases, coronary heart disease, schizophrenia, multiple sclerosis, and stroke. CNS biomarker market in the US is booming with early adoption of latest technologies (for example proximity extension assay) and growing research and development in life science research. Increasing prevalence of lifestyle diseases like Alzheimer’s, cardiovascular disease, coronary heart disease, cancer and stroke and rising aging population are the main drivers of the CNS biomarker market in the US. On the other hand, Asia-Pacific is anticipated to be the fastest-growing region for the Central Nervous System (CNS) biomarker market.

The Central Nervous System (CNS) biomarker Market is segmented based on types which are sub-divided into safety biomarker, efficacy biomarker, validation biomarker; and also on the basis of end users which are sub-divided into hospitals, eye clinics, diagnostic centers, patients and other end users. The growing clinical research becomes a major driver for the safety biomarkers. The efficacy biomarkers are used in cases where tumors are resected from patients prior to therapies and surgeries are not normally obligatory until the disease persists. The biomarker validation is the important process for the use of newly developed drugs and devices. The growing number of hospitals in developed (ex:- US, Canada) and developing(ex:- India, China) countries help to increase the demand of CNS biomarker market, globally. The growing eye diseases are the major concern in both developed and developing countries. The growing aging population and the rising cases of cancer are the major drivers responsible for increasing the demand of CNS biomarker in the diagnostic centers.

The major market players in the global Central Nervous System (CNS) biomarker market are:

  • Acumen Pharmaceuticals Inc.
  • Avid Radiopharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Enzo Biochem Inc.
  • Proteome Sciences Plc.

Company Profiles covers analysis of important players.

Thermo Fisher Scientific Inc. manufactures, develops, and provides reagents, analytical equipment, software and services, instruments, and consumables, for manufacturing, research, discovery, analysis, and diagnostics. The company offers products and services under five principal brands which include: Fisher Scientific, Applied Biosystems, Invitrogen, Unity Lab Services and Thermo Scientific. Enzo Biochem, is a vertically integrated bioscience company focused on developing biological processes to establish research tools, therapeutics, and diagnostics and serve as a provider of test services. It developed a portfolio of proprietary technologies with a range of research, diagnostic and therapeutic applications including gene analysis technology, cell signaling pathway, and oral immune regulation.

Key Findings of the Global Central Nervous System (CNS) biomarker market:

  • Asia Pacific regions hold the potential growth opportunities
  • Increasing application of biomarkers in the drug discovery and development
  • Increase in number of patients suffering from brain tumor
  • Efficacy biomarker held the largest market share in 2016
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • ASIA PACIFIC REGIONS HOLD THE POTENTIAL GROWTH OPPORTUNITIES
      • INCREASING APPLICATION OF BIOMARKERS IN THE DRUG DISCOVERY AND DEVELOPMENT
      • INCREASE IN NUMBER OF PATIENTS SUFFERING FROM BRAIN TUMOR
      • EFFICACY BIOMARKER HELD THE LARGEST MARKET SHARE IN 2016
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • INCREASING USAGE OF GENOMICS, METABOLOMICS, PROTEOMICS, AND BIOINFORMATICS
      • FUNDING BY THE FRAMEWORK PROGRAMS FOR RESEARCH AND DEVELOPMENT OF TECHNOLOGY
      • OBESITY HAS BECOMING A MAJOR CONCERN
      • PUBLIC-PRIVATE CORPORATION HAS ESCALATED
      • UPSURGE IN BIOMARKER MARKET DUE TO FDA SUPPORTS
      • NEW INNOVATIONS AND TECHNOLOGICAL ADVANCEMENT IN BIOMARKER MARKET
      • RISE IN REAL PER CAPITA HEALTHCARE
    • MARKET RESTRAINTS
      • REIMBURSEMENT POLICIES DISTRESSING THE CNS BIOMARKER MARKET
      • CNS BIOMARKER TEST AND DIAGNOSTICS INCLUDES HIGH COST
    • MARKET OPPORTUNITIES
      • PERSONALIZED MEDICINE PROVIDES NEW WAY FOR DRUG DEVELOPMENT
      • ASIA PACIFIC IS A HIGH POTENTIAL MARKET FOR CNS BIOMARKER
      • INCREASING GERIATRIC POPULATION
      • POLICIES AND FUNDING INITIATIVE TAKEN BY THE GOVERNMENT
    • MARKET CHALLENGES
      • LACK OF AWARENESS REGARDING CNS BIOMARKER
      • ECONOMIC SLOWDOWN MIGHT DISTRESS THE CNS BIOMARKER MARKET
      • SAMPLE COLLECTION AND STORAGE IS A MAJOR CHALLENGE
  1. MARKET SEGMENTATION
    • MARKET BY APPLICATION 2017-2025
      • DIAGNOSTIC DEVELOPMENT
      • DRUG DISCOVERY AND DEVELOPMENT
      • PERSONALIZED MEDICINE MARKET
      • DISEASE RISK ASSESSMENT
      • OTHER APPLICATION
    • MARKET BY TYPE 2017-2025
      • SAFETY BIOMARKER
      • EFFICACY BIOMARKER
        • PREDICTIVE BIOMARKER
        • PHARMACODYNAMICS BIOMARKER
        • PROGNOSTIC BIOMARKER
      • VALIDATION BIOMARKER
    • MARKET BY END USERS 2017-2025
      • HOSPITALS
      • EYE CLINICS
      • DIAGNOSTIC CENTERS
      • PATIENTS
  1. KEY ANALYTICALS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
    • OPPORTUNITY MATRIX
    • STRATEGIC RECOMMENDATION
    • STRATEGIC CONCLUSIONS
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM (UK)
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • REST OF APAC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND NORTH AFRICA
      • REST OF AFRICA
  1. COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS
    • TOP WINNING STRATEGIES
  2. COMPANY PROFILE
    • ACUMEN PHARMACEUTICALS, INC.
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • ALSERES PHARMACEUTICALS INC.
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
    • APITOPE INTERNATIONAL
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • AVACTA GROUP PLC
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • AVID RADIOPHARMACEUTICALS INC.
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • BANYAN BIOMARKERS.
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • DIAGENIC ASA
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
    • EKF DIAGNOSTICS
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • ENZO BIOCHEM INC
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • EXONHIT THERAPEUTICS
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • MYRIAD RBM, INC (SUBSIDIARY OF MYRIAD GENETICS)
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • PROTEOME SCIENCES
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES
    • THERMO FISHER SCIENTIFIC
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • PRODUCT PORTFOLIO
      • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE 1        GLOBAL CNS BIOMARKER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 2        BIOMARKER DRUG DIAGNOSTIC PRICE

TABLE 3        GLOBAL CNS BIOMARKER MARKET BY APPLICATION2017-2025 ($ MILLION)

TABLE 4        GLOBAL DIAGNOSTIC DEVELOPMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 5        GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 6        GLOBAL PERSONALIZED MEDICINE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 7        GLOBAL DISEASE RISK ASSESSMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 8        GLOBAL OTHER APPLICATION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 9        GLOBAL CNS BIOMARKER MARKET BY TYPE 2017-2025($ MILLION)

TABLE 10      GLOBAL EFFICACY BIOMARKER MARKET 2017-2025($ MILLION)

TABLE 11      GLOBAL CNS BIOMARKER MARKET BY END USERS 2017-2025($ MILLION)

TABLE 12      NUMBER OF PERSONS WITH OPEN-ANGLE GLAUCOMA IN UNITED STATES, 2015 -2035(MILLION)

TABLE 13      GLOBAL CNS BIOMARKER MARKET BY REGION 2017-2025 ($ MILLION)

TABLE 14      NORTH AMERICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

TABLE 15      EUROPE CNS BIOMARKER MARKET 2017-2025

TABLE 16      ASIA PACIFIC CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

TABLE 17      PREVALENCE RATE OF DEMENTIA IN REST OF APAC WITH ESTIMATED TREATMENT COST

TABLE 18      REST OF WORLD CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

TABLE 19      TOP STRATEGIES

LIST OF FIGURES

FIGURE 1      GLOBAL CNS BIOMARKERS MARKET 2017-2025 ($ MILLION)

FIGURE 2      OBESE POPULATION COUNTRIES (%)

FIGURE 3      GLOBAL DIAGNOSTIC DEVELOPMENT MARKET 2017-2025 ($ MILLION)

FIGURE 4      GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET 2017-2025 ($ MILLION)

FIGURE 5      PERSONALIZED MEDICINE IN TERMS OF USAGE

FIGURE 6      GLOBAL PERSONALIZED MEDICINE MARKET2017-2025 ($ MILLION)

FIGURE 7      GLOBAL DISEASE RISK ASSESSMENT MARKET2017-2025 ($ MILLION)

FIGURE 8      GLOBAL OTHER APPLICATION MARKET 2017-2025 ($ MILLION)

FIGURE 9      GLOBAL SAFETY BIOMARKER MARKET 2017-2025($ MILLION)

FIGURE 10   GLOBAL PREDICTIVE BIOMARKER MARKET 2017-2025($ MILLION)

FIGURE 11   GLOBAL PHARMACODYNAMICS BIOMARKER MARKET, 2017-2025($ MILLION)

FIGURE 12   GLOBAL PROGNOSTIC BIOMARKER MARKET 2017-2025($ MILLION)

FIGURE 13   GLOBAL VALIDATION BIOMARKER MARKET, 2017-2025($ MILLION)

FIGURE 14   GLOBAL HOSPITALS CNS BIOMARKER MARKET, 2017-2025,($MILLION)

FIGURE 15   GLOBAL EYE CLINICS CNS BIOMARKER MARKET 2017-2025($MILLION)

FIGURE 16   GLOBAL DIAGNOSTIC CENTERS CNS BIOMARKER MARKET 2017-2025 ($MILLION)

FIGURE 17   GLOBAL NEW CANCER CASES AND MOTILITY RATE 2015 & 2030 (MILLION)

FIGURE 18   GLOBAL PATIENTS CNS BIOMARKER MARKET 2017-2025($MILLION)

FIGURE 19   PORTER’S FIVE FORCE MODEL IN CNS BIOMARKERS MARKET

FIGURE 20   UNITED STATES CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 21   CANADA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 22   UNITED KINGDOM CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 23   FRANCE CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 24   GERMANY CNS BIOMARKER MARKET2017-2025 ($ MILLION)

FIGURE 25   SPAIN CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 26   ITALY CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 27   REST OF EUROPE CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 28   PERCENTAGE OF TOTAL POPULATION LIVING WITH DEMENTIA IN REST OF EUROPE

FIGURE 29   INDIA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 30   CHINA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 31   JAPAN CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 32   REST OF APAC CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 33   LATIN AMERICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 34   MENA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 35   REST OF AFRICA CNS BIOMARKER MARKET 2017-2025 ($ MILLION)

FIGURE 36   MARKET SHARE ANALYSIS OF CNS MARKET (2016)

  1. MARKET SEGMENTATION
    • MARKET BY APPLICATION 2017-2025
      • DIAGNOSTIC DEVELOPMENT
      • DRUG DISCOVERY AND DEVELOPMENT
      • PERSONALIZED MEDICINE MARKET
      • DISEASE RISK ASSESSMENT
      • OTHER APPLICATION
    • MARKET BY TYPE 2017-2025
      • SAFETY BIOMARKER
      • EFFICACY BIOMARKER
        • PREDICTIVE BIOMARKER
        • PHARMACODYNAMICS BIOMARKER
        • PROGNOSTIC BIOMARKER
      • VALIDATION BIOMARKER
    • MARKET BY END USERS 2017-2025
      • HOSPITALS
      • EYE CLINICS
      • DIAGNOSTIC CENTERS
      • PATIENTS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM (UK)
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • REST OF APAC
    • REST OF THE WORLD

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now